Related Experiment Video

Updated: May 25, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell

Roberto Gedaly1, Paul Angulo, Jonathan Hundley

  • 1Department of Surgery, University of Kentucky, College of Medicine, Lexington, Kentucky 40536-0293, USA. rgeda2@uky.edu

The Journal of Surgical Research
|January 21, 2012
PubMed
Abstract

Insights

The combination of PKI-587 and sorafenib effectively inhibits hepatocellular carcinoma (HCC) cell proliferation by targeting both the PI3K/AKT/mTOR and Ras/Raf/MAPK pathways, showing greater efficacy than single-drug treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Hepatocellular carcinoma (HCC) is characterized by dysregulated signaling in the Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
  • Targeting these pathways is crucial for developing effective HCC therapies.
  • This study investigates the potential of PKI-587 and sorafenib in combating HCC.

Purpose of the Study:

  • To evaluate the inhibitory effects of PKI-587 and sorafenib on HCC (Huh7 cell line) proliferation.
  • To compare the efficacy of PKI-587 and sorafenib as single agents versus their combination.
  • To analyze the impact of these agents on key signaling pathway components.

Main Methods:

  • Cell proliferation was assessed using (3)H-thymidine incorporation and MTT assays.
  • Western blotting was employed to detect the phosphorylation status of key signaling enzymes.
  • The study focused on the Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.

Main Results:

  • PKI-587 demonstrated potent inhibition of PI3K/mTOR signaling.
  • The combination of PKI-587 and sorafenib synergistically inhibited HCC cell proliferation, outperforming monotherapy and combinations with PI-103.
  • Combined therapy effectively blocked phosphorylation of kinases in both Ras/Raf/MAPK and PI3K/AKT/mTOR pathways, while single agents had varied effects.

Conclusions:

  • The combination of PKI-587 and sorafenib offers a superior therapeutic strategy for HCC compared to monotherapy.
  • This combination effectively inhibits HCC cell proliferation by simultaneously targeting both the PI3K/AKT/mTOR and Ras/Raf/MAPK signaling cascades.
  • The findings support the development of dual-targeting therapies for hepatocellular carcinoma.

More Related Videos

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...